Novel drug delivery approaches on antiviral and antiretroviral agents

Journal of Advanced Pharmaceutical Technology and Research

Volumn 3, Issue 3, 2012, Pages 147-159

  Arora, Sandeep ^a   Chawla, Anuj ^a   Pawar, Pravin ^a   Sharma, Pooja ^a  

^a CHITKARA UNIVERSITY   (India)

Author keywords

antiviral agents; herpes viruses; HIV; NDDS; viral infections

Indexed keywords

ACICLOVIR; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; ATAZANAVIR; BETA CYCLODEXTRIN; CHICKENPOX VACCINE; CIDOFOVIR; DRUG CARRIER; ETHOSOME; FAMCICLOVIR; FOSCARNET; GANCICLOVIR; GLYCYRRHIZIC ACID; IDOXURIDINE; INDINAVIR; LIPOSOME; MACROGOL; NANOPARTICLE; NEVIRAPINE; NIOSOME; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PENCICLOVIR; POLYMER; RNA DIRECTED DNA POLYMERASE INHIBITOR; SOLID LIPID NANOPARTICLE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALACICLOVIR; VALGANCICLOVIR; VARICELLA ZOSTER VACCINE; WART VIRUS VACCINE;

ADENOVIRUS INFECTION; ADVERSE DRUG REACTION; ANUS CANCER; BIOCOMPATIBILITY; BIODEGRADABILITY; BONE MARROW TOXICITY; CHICKENPOX; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; CYTOMEGALOVIRUS INFECTION; DNA VIRUS; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG SYNTHESIS; FIRST PASS EFFECT; GENITAL HERPES; HERPES LABIALIS; HERPES SIMPLEX; HERPES SIMPLEX KERATITIS; HERPES ZOSTER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN T CELL LEUKEMIA VIRUS; KAPOSI VARICELLIFORM ERUPTION; KERATOCONJUNCTIVITIS; MICROEMULSION; NANOPHARMACEUTICS; NEPHROTOXICITY; NONHUMAN; NOVEL DRUG DELIVERY SYSTEM; PAPILLOMAVIRUS INFECTION; PATIENT COMPLIANCE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RNA VIRUS; TREATMENT DURATION; UTERINE CERVIX CANCER; VIRAL SKIN DISEASE;

EID: 84866422700     PISSN: 22314040     EISSN: 09762094     Source Type: Journal    
DOI: 10.4103/2231-4040.101007     Document Type: Conference Paper

References (83)

1. Lwoff A, Horne R, Tournier P. A system of viruses. Cold Spring Harb Symp Quant Biol 1962;27:51-5.
2. Rang HP, Dale MM, Ritter JM, Moore PK, editors. Pharmacology. 5th ed. New Delhi: Elsevier; 2007. p. 655.
3. Olson J, Robles DT, Kirby P, Kirby P, Colvev R. Kaposi varicellform eruption (eczema herpeticum). Dermatol Online J 2008;14:18.
4. David TJ, Longson M. Herpes simplex infections in atopic eczema. Arch Dis Child 1985;4:338-43.
5. Buchan J. Characteristics of orf in a farming community in mid-Wales. BMJ 1996;7051:203-4.
6. Whitley RJ, Griffths PD. Herpesviruses: An Introduction with a focus of Herpes simplex virus. In: Boucher CAB, Galasso GA, Katzenstein DA, Cooper DA, editors. Practical guidelines in antiviral therapy. Amsterdam: Elsevier Science B.V; 2002. p. 127-49.
7. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002;347:1645-51.
8. Marin M, Guris D, Chaves SS, Schmid S, Seward JF. Prevention of varicella; recommendation of the advisory committee on immunization practises (ACIP). MMWR Recomm Rep 2007;RR04:1-40.
9. Johnson RW, Dworkin RH. Treatment of Herpes zoster and postherpetic neuralgia. BMJ 2003;326:748-50.
10. Benson HA. Transdermal drug delivery: Penetration enhancement techniques. Current Drug Deliv 2005;2:23-33.
11. Holmes EM, Breytenbach JC, Gerber M, du Plessis J. Synthesis and transdermal penetration of stavudine-5′-esters. Med Chem 2010;6:271-6.
12. Peira E, Chirio D, Carlotti ME, Spagnolo R, Trotta M. Formulation studies of microemulsions for topical applications of acyclovir. J Drug Deliv Sci Technol 2009;19:191-96.
13. Chudasaina A, Patel VK, Nivsarkar M, Vasu K, Shishoo C. Investigation of microemulsion system for transdermal delivery of itraconazole. J Adv Pharm Technol Res 2011;2:30-8.
14. Mnjunatha N, Naidu GP, Sutrave V, Patel K, Samanta MK. Preparation and evaluation of liposomes of an antiviral drug. Indian Journal of Novel Drug Delivery 2009;1:25-31.
15. Owens DE, Peppas NA. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm 2006;307:93-102.
16. Zhang XG, Miao J, Li MW, Jiang SP, Hu FQ, Du YZ. Solid lipid nanoparticles loading adefovir dipivoxil for antiviral therapy. J Zhejiang Univ Sci B 2008;9:506-10.
17. Chattopadhyay N, Zastre J, Wong HL, Bendayan R. Solid lipid nanoparticles enhance the delivery of the HIV protease inhibitor, atazanavir, by a human brain endothelial cell line. Pharm Res 2008;25:2262-71.
18. Dehghan MHG. Advances in iontophoresis for drug delivery. Int J Health Res 2008;1:115-27.
19. Verma P, Pathak K. Therapeutic and cosmeceutical potential of ethosomes: An overview. J Adv Pharm Technol Res 2010;1:274-82.
20. De Jalon EG, Blanco-Prieto MJ, Ygartua P, Santoyo S. Topical application of acyclovir-loaded microparticles: Quantification of the drug in porcine skin layers. J Control Release 2001;75:191-7.
21. Available from: http://www.allaboutvision.com/conditionss/ocullar- herppes.htm.
22. Deshpande PB, Dandagi P, Udupa N, Goal SV, Jain SS, Vasanth SG. Controlled release polymeric ocular delivery of acyclovir. Pharm Dev Technol 2010;15:369-78.
23. Kumari A, Sharma PK, Garg VK, Garg G. Ocular inserts-advancement in therapy of eye diseases. J Adv Pharm Technol Res 2010;1:291-6.
24. Date HL, Fisher M. HIV infection. In: Walker R, Whittlesea C, editors. Clinical pharmacy and therapeutics. New York: Churchill Livingstone Elsevier; 2007. p. 568-9.
25. Srikanth BA, Babu SC, Yadav HN, Jain SK. Incidence of adverse drug reactions in human immune deficiency virus-positive patients using highly active antiretroviral therapy. J Adv Pharm Technol Res 2012;3:62-7.
26. Rosenblatt JD, Chen IS, Wachsman W. Infection with HTLV-I and HTLV-II: Evolving concepts. Semin Hematol 1988;25:230-46.
27. Arora SC, Sharma PK, Irchhaiya R, Khatkar A, Singh N, Gagoria J. Development, characterization and solubility study of solid dispersions of cefuroxime axetil by the solvent evaporation method. J Adv Pharm Technol Res 2010;1:326-9.
28. Damian F, Blaton N, Naesens L, Balzarini J, Kinget R, Augustijns P, et al. Physicochemical characterization of solid dispersions of the antiviral agent UC-781 with polyethylene glycol 6000 and gelucire 44/14. Eur J Pharm Sci 2000;4:311-22.
29. Bollam S, Kandadi P, Apte SS, Veerabrahma K. Development of indinavir submicron lipid emulsions loaded with lipoamino acids-in vivo pharmacokinetics and brain-specific delivery. AAPS PharmSciTech 2011;12:422-30.
30. Vajpayee M, Malhotra N. Antiviral drugs against herpes infections. Indian J Pharmacol 2000;32:330-8.
31. Seth AK, Misra A, Umrigar D. Topical liposomal gel of idoxuridine for the treatment of herpes simplex: Pharmaceutical and clinical implications. Pharm Dev Technol 2004;9:277-89.
32. Touitou E, Segal R, Pisanty S, Milogoldzweig I. Glycyrrhizin gel as vehicle for idoxuridine topical preparation: Skin permeation behaviour. Drug Des Deliv 1988;3:267-72.
33. Kokate CK, Purohit AP, Gokhale SB. Pharmacognosy. 38th ed. Pune: Nirali Prakashan; 2007. p. 214.
34. Reardon JE, Spector T. Herpes simplex virus Type I DNA polymerase mechanism of inhibition by acyclovir triphosphate. J Biol Chem 1989;264:7405-11.
35. Beutner KR. Valciclovir: A review of its antiviral activity, pharmacokinetic properties and clinical efficacy. Antiviral Res 1995;28:281-90.
36. Trying SK, Baker D, Snowden W. Valacyclovir for Herpes simplex virus infection: Long-term safety and sustained afficacy after 20 years' experience with acyclovir. J Infect Dis 2002;186:S40-6.
37. Waqstaff AJ, Faulds D, Goa KL. Aciclovir. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1994;47:153-205.
38. Shishu, Rajan S, Kamalpreet. Development of novel microemulsionbased topical formulations of acyclovir for the treatment of cutaneous herpetic infections. A APS Pharm Sci Tech. 2009;10:559-65.
39. Chetoni P, Rossi S, Burgalassi S, Monti D, Mariotti S, Saettone MF. Comparison of liposome-encapsulated acyclovir with acyclovir ointment: Ocular pharmacokinetics in rabbits. J Ocul Pharmacol Ther 2004;20:169-77.
40. Siddoju S, Sachdeva V, Friden PM, Yu YY, Banga AK. Acyclovir skin depot characterization following in vivo iontophoretic delivery. Skin Res Technol 2011;2:234-44.
41. Maudgal PC, De Clercq K, Descamps J, Missotten L. Topical treatment of experimental herpes simplex keratouveitis with 2′-O-glycylacyclovir. A water-soluble ester of acyclovir. Arch Ophthalmol 1984;102:140-2.
42. Deshpande PB, Dandagi P, Udupa N, Gopal SV, Jain SS, Vasanth SG. Controlled release polymeric ocular delivery of acyclovir. Pharm Dev Technol 2010;15:369-78.
43. Abla N, Naik A, Guy RH, Kalia YN. Topical iontophoresis of valaciclovir hydrochloride improves cutaneous aciclovir delivery. Pharm Res 2006;23:1842-9.
44. Hillenkamp J, Reinhard T, Ross RS, Böhringer D, Cartsburg O, Roggendorf M, et al. The effects of cidofovir 1% with and without cyclosporin a 1% as a topical treatment of acute adenoviral keratoconjunctivitis: A controlled clinical pilot study. Ophthalmology 2002;109:845-50.
45. Martinez CM, Luks-Golger DB. Cidofovir use in acyclovir-resistant herpes infection. Ann Pharmacother 1997;31:1519-21.
46. Sonvico F, Colombo G, Gallina L, Bortolotti F, Rossi A, Mclnes CJ, et al. Therapeutic paint of cidofovir/sucralfate gel combination topically administered by spraying for treatment of orf virus infections. AAPS PharmSciTech 2009;11:242-9.
47. Sacks SL. Famciclovir (FAMVIR®). Infect Dis obstet Gynecol 1997;5:3-7.
48. Tripathi KD. Essentials of Medical Pharmacology. 6th ed. New Delhi: Jaypee Brothers Medical Publishers (P) Ltd; 2008. p. 769.
49. Vere Hodge RA, Sutton D, Boyd MR, Harden MR, Jarvest RL. Selection of an oral prodrug (BRL 42810; famciclovir) for the anti herpes virus agent BRL 39123[9-(4-hydroxy-3-hydroxymethylbut-1-yl) guanine; penciclovir. Antimicrob Agents Chemother 1989;33:1765-73.
50. Zhu W, Guo C, Yu A, Gao Y, Cao F, Zhi G. Microemulsionbased hydrogel formulation of penciclovir for topical delivery. Int J Pharm 2009 13;378:152-8.
51. Zhu W, Yu A, Wang W, Dong R, Wu J, Zhai G. Formulation design of microemulsion for dermal delivery of penciclovir. Int J Pharm 2008;360:184-90.
52. Malakar J, Sen SO, Nayak AK, Sen KK. Development and evaluation of microemulsions for transdermal delivery of insulin. ISRN Pharm 2011;2011:1-7.
53. Kaur IP, Kakkar S. Topical delivery of antifungal agents. Expert Opin Drug Deliv 2010;7:1303-27.
54. Lv Q, Yu A, Xi Y, Li H, Song Z, Cui J, et al. Development and evaluation of penciclovir-loaded solid lipid nanoparticles for topical delivery. Int J Pharm 2009;372:191-8.
55. Loutsch JM, Sainz B, Marquart ME, Zheng X, Kesavan P, Higaki S, et al. Effect of famciclovir on Herpes simplex virus type 1 corneal disease and establishment of latency in rabbits. Antimicrob Agents Chemother 2001;45:2044-53.
56. Chirsp P, Clissold SP. Foscarnet: A Review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with Cytomegalovirus retinitis. Drugs 1991;41:104-29.
57. Piret J, Lamontagne J, Desormeaux A, Bergeron MG. Efficacies of gel formulations containing foscarnet, alone or combined with sodium lauryl sulfate, against establishment and reactivation of latent Herpes simplex virus type 1. Antimicrob Agents Chemother 2001;45:1030-6.
58. Piret J, Desormeaux A, Cormier H, Lamontanqne J, Gourde P, Juhasz J, et al. Sodium lauryl sulfate increases the efficacy of a topical formulation of foscarnet against Herpes simplex virus type 1 cutaneous lesions in mice. Antimicrob Agents Chemother 2000;44:2263-70.
59. Bernstein DI, Schleupner CJ, Evans TG. Effect of foscarnet cream on experimental UV radiation-induced Herpes labialis. Antimicrob Agents Chemother 1997;41:1961-4.
60. Crumpacker CS. Ganciclovir. N Engl J Med 1996;335:721-9.
61. Tabbara KF, Balushin NA. Topical ganciclovir in the treatment of acute herpetic keratitis. Clin Ophthalmol 2010;4:905-12.
62. Colin J, Hoh HB, Easty DL, Herbort CP, Resnikoff S, Rigal D, et al. Ganciclovir ophthalmic gel (Virgan; 0.15%) in the treatment of Herpes simplex keratitis. Cornea 1997;16:393-9.
63. Herrero-Vanrell R, Ramirez L, Fernandez-Carballido A, Refojo MF. Biodegradable PLGA microspheres loaded with ganciclovir for intraocular administration. encapsulation technique, in vitro release profiles, and sterilization process. Pharm Res 2000;17:1323-8.
64. Chang M, Dunn JP. Ganciclovir implant in the treatment of Cytomegalovirus retinitis. Br J Ophthalmol 2010;94:1648-52.
65. Porter RS, Kaplan JL, editors. The merck manual: The merck manual of diagnosis and therapy. 19th ed. N.J.: Merck Sharp and Dohme Corp.; 2004-2011.
66. Castiglione F, Pappalardo F, Bernaschi M, Motta S. Optimization of HAART with genetic algorithms and agent-based models of HIV infection. Bioinformatics 2007;23:3350-55.
67. Warnke D, Barreto J, Temesgen Z. Antiretroviral drugs. J Clin Pharmacol 2007;47:1570-79.
68. Vyas SP, Subhedar R, Jain S. Development and characterization of emulsomes for sustained for sustained and targeted delivery of an antiviral agent to liver. J Pharm Pharmacol 2006;58:321-6.
69. Available from: http://www.ncbi.nLm.nih.gov/pccompound?term=zalcitabine.
70. Kim DD, Chein YW. Transdermal delivery of zalcitabine: In vitro skin permeation study. AIDS 1995;9:1331-6.
71. Babu BA, Ramu G, VenkataRao S. Spectrophotometric determination of an antiretroviral drug stavudine in bulk and pharmaceutical formulations. Rasayan J Chem 2011;4:336-42.
72. Inoue H, Sonoda KH, Ishikawa M. Clinical evaluation of local ocular toxicity in candidate anti-adenoviral agents in vivo. Ophthalmologica 2009;223:233-8.
73. N'Da DD, Breytenbach JC, Legoabe LJ, Breytenbach JW. Synthesis and in vitro transdermal penetration of methoxypoly (ethylene glycol) carbonate derivative of stavudine. Med Chem 2009;5:497-506.
74. Jain S, Tiwary AK, Sapra B, Jain NK. Formulation and evaluation of ethosomes for transdermal delivery of lamivudine. AAPS PharmSciTech 2007;8:E111.
75. Murphy R, Montaner J. Nevirapine: A Review of its development, pharmacological profile and potential for clinical use. Exp Opin Invest Drugs 1996;5:1183-99.
76. Ramana LN, Sethuraman S, Ranga U, Krishnan UM. Development of a liposomal nanodelivery system for nevirapine. J Biomed Sci 2010;17:57.
77. Chiappetta DA, Hocht C, Taira C, Sosnik A. Efaviranz-loaded polymeric micelles for pediatric anti-HIV pharmacotherapy with significantly higher oral bioavailability. Nanomedicine 2010;5:11-23.
78. Fayet MA, Buclin T, Decosterd LA, Delhumeau C, di lulio J, Fleurent A, et al. Successful efavirenz dose reduction guided by therapeutic drug monitoring. Antivir Ther 2011;16:189-97.
79. Rang HP, Dale MM, Ritter JM, Moore PK, editors. Pharmacology. 5th ed. New Delhi: Elsevier; 2007. p. 661.
80. Hull MW, Montaner JS. Ritonavir-boosted protease inhibitors in HIV therapy. Ann Med 2011; 43:375-88.
81. Sinha S, Ali M, Baboota S, Ahuja A, Kumar A, Ali J. Solid-dispersion as an approach for bioavailability enhancement of poorly water-soluble drug ritonavir. AAPS PharmSciTech 2010;11:518-27.
82. Jain V, Prasad V, Jadhav P, Mishra PR. Preparation and performance evaluation of saquinavir laden cationic submicron emulsions. Drug Deliv 2009;16:37-44.
83. Galor A, Karp CL, Chhabra S, Barnes S, Alfonso EC. Topical interferon alpha 2b eye-drops for treatment of ocular surface squamous neoplasia: A dose comparison study. Br J Ophthalmol 2010;5:551-4.